PPA
ACRS icon

Parametric Portfolio Associates’s Aclaris Therapeutics ACRS Stock Holding History

Parametric Portfolio Associates’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$784K Buy
45,497
+20,364
+81% +$278K ﹤0.01% 2891
2021
Q4 		$365K Buy
25,133
+5,360
+27% +$81.2K ﹤0.01% 3203
2021
Q3 		$356K Buy
+19,773
New +$317K ﹤0.01% 3233
2021
Q2 		– Sell
-84,276
Closed -$2.12M – 3559
2021
Q1 		$2.12M Buy
+84,276
New +$1.65M ﹤0.01% 2741
2020
Q2 		– Sell
-18,418
Closed -$19K – 3909
2020
Q1 		$19K Sell
18,418
-112,147
-86% -$153K ﹤0.01% 3895
2019
Q4 		$247K Buy
130,565
+105,349
+418% +$175K ﹤0.01% 3659
2019
Q3 		$27K Sell
25,216
-65,651
-72% -$93.1K ﹤0.01% 3921
2019
Q2 		$199K Buy
90,867
+33,646
+59% +$183K ﹤0.01% 3740
2019
Q1 		$343K Sell
57,221
-39,201
-41% -$260K ﹤0.01% 3500
2018
Q4 		$713K Sell
96,422
-7,604
-7% -$78.4K ﹤0.01% 3154
2018
Q3 		$1.51M Sell
104,026
-7,339
-7% -$126K ﹤0.01% 2888
2018
Q2 		$2.22M Buy
111,365
+66,254
+147% +$1.22M ﹤0.01% 2615
2018
Q1 		$790K Buy
45,111
+20,077
+80% +$425K ﹤0.01% 3129
2017
Q4 		$617K Buy
25,034
+2,218
+10% +$54K ﹤0.01% 3235
2017
Q3 		$589K Sell
22,816
-5,427
-19% -$145K ﹤0.01% 3325
2017
Q2 		$766K Sell
28,243
-27,154
-49% -$738K ﹤0.01% 3129
2017
Q1 		$1.65M Buy
55,397
+22,223
+67% +$641K ﹤0.01% 2572
2016
Q4 		$900K Buy
+33,174
New +$846K ﹤0.01% 2898

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Parametric Portfolio Associates's ACRS Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Aclaris Therapeutics (ACRS) stake by 81% in Q1 2022, buying an estimated $278K and bringing the position to 45,497 shares worth $784K. The position accounts for ﹤0.01% of the portfolio, ranked #2891.

Parametric Portfolio Associates first reported a position in ACRS in Q4 2016 and has held it in 18 quarters since. The position peaked at $2.22M in Q2 2018. 110 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Parametric Portfolio Associates held 45,497 shares of Aclaris Therapeutics worth $784K as of Q1 2022.
  • Parametric Portfolio Associates bought 20,364 Aclaris Therapeutics shares in Q1 2022, an estimated $278K.
  • Aclaris Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2891 holding.
  • Parametric Portfolio Associates first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 18 quarters since.
  • Parametric Portfolio Associates's Aclaris Therapeutics position peaked at $2.22M in Q2 2018.
  • 110 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.